Understanding the CAGR Trends: Global Point of Care Diagnostics Market to grow at CAGR of 6.61% by 2028, Anticipates DelveInsight | Hoffmann-La Roche Ltd., BD, Danaher, Abbott, Siemens Healthcare Private Limited, Nova Biomedical, Quidel Corporation, Chemb

As per DelveInsight's assessment, the Point of Care Diagnostics Market is expected to grow at an immense pace in the coming years owing to the The increasing prevalence of pandemic such as COVID-19, Pre- and post-operation and some few of the other applications where Point of Care Diagnostics have been used, which is expected to drive the demand for Point of Care Diagnostics in the upcoming years.

DelveInsight's "Point of Care Diagnostics Market" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Point of Care Diagnostics companies actively working in the market.

Point of Care Diagnostics Overview
https://www.delveinsight.com/sample-request/point-of-care-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Point of Care With the use of a range of diagnostic tests conducted nearby, usually in clinics, hospitals, and patients' homes, diagnostics are instruments that enable prompt evaluation of a patient's health.

Point of Care Diagnostics Market Insights
The need for point-of-care diagnostics will rise in tandem with the growing number of diabetic patients. The point-of-care diagnostics market will be stimulated by the increasing use of these devices by individuals to track their health status on a regular basis or to identify any potential abnormalities in their vital signs that could lead to an early diagnosis of a variety of diseases.

DelveInsight Analysis: The Global Point of Care Diagnostics market size is anticipated to grow with a CAGR of 6.61% during the forecasted period (2023-2028).

To know more about why North America is leading the market growth in the Point of Care Diagnostics market, get a snapshot of the report Point of Care Diagnostics Market Trends
https://www.delveinsight.com/report-store/point-of-care-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Recent Developments in the Point of Care Diagnostics Market Report
• In January 2023, Cipla announced the launch of a point of care testing device named Cippoint which offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and others.
• In August 2022, Precision Diabetes, Inc. and DxGen Corp., entered into an exclusive agreement in the US to launch Epithod® AutoDx, a fully-automatic point of care (POC) analyzer that measures a comprehensive profile of diabetes tests.
• In July 2021, QuantuMDx Group Limited, a UK-based developer of transformational point of care diagnostics, announced the launch of Q-POC™ - a rapid, PCR point of care diagnostic system in the UK.

To read more about the latest highlights related to Point of Care Diagnostics, get a snapshot of the key highlights entailed in the Point of Care Diagnostics Market Forecast Report
https://www.delveinsight.com/sample-request/point-of-care-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Key Players in the Point of Care Diagnostics Market
Some of the key market players operating in the Point of Care Diagnostics market include- F. Hoffmann-La Roche Ltd., BD, Danaher, Abbott, Siemens Healthcare Private Limited, Nova Biomedical, Quidel Corporation, Chembio Diagnostics, Inc., EKF Diagnostics Holdings plc., Trinity Biotech, Fluxergy, Thermo Fisher Scientific, Quest Diagnostics Incorporated, DiaSys Diagnostics India Pvt Ltd., Cipla, Sysmex Europe SE, Lumos Diagnostics™, Trivitron Healthcare, Getein Biotech, Inc., ACON Laboratories, Inc., and others.

COVID-19 Impact Analysis on the Point of Care Diagnostics Market
According to estimates, North America will hold the most proportion of the global point-of-care diagnostics market in 2022. The market for point of care diagnostics is anticipated to flourish in the region during the forecast period 2023-2028 due to the significance of key growth factors like the rising prevalence of infectious diseases, the rising number of cases of diabetes and other lifestyle-based diseases, high disposable income, sophisticated healthcare infrastructure, presence of key players, increasing product development activities, and others.
Additionally, The introduction of the COVID-19 infection has had a positive impact on the point-of-care diagnostics business. Despite the unexpected and catastrophic effects of the COVID-19 pandemic, the demand for point-of-care diagnostics was positively impacted because the POC diagnostic was quickly utilized to diagnose COVID-19. Rapid antigen testing kits that work well in point-of-care settings are in high demand due to the rapidly increasing number of COVID-19 cases and the mounting pressure on the government to improve patient management. So, during the projected period, the market for Point of Care Diagnostics is anticipated to continue expanding (2023-2028).

Scope of the Point of Care Diagnostics Market Report
• Coverage: Global
• Study Period: 2020-2028
• Point of Care Diagnostics Market Segmentation By Product Type: Instruments, Kits And Reagents
• Point of Care Diagnostics Market Segmentation By Application: Blood Glucose Monitoring, Infectious Diseases, Cardio-Metabolic Diseases, Pregnancy & Fertility Testing, And Others
• Point of Care Diagnostics Market Segmentation By End User: Hospitals, Diagnostic Centers, Home Care Settings, And Others
• Point of Care Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
• Key Point of Care Diagnostics Companies: Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Bayer AG, Bristol-Myers Squibb, Eli Lilly and CoF. Hoffmann-La Roche Ltd., BD, Danaher, Abbott, Siemens Healthcare Private Limited, Nova Biomedical, Quidel Corporation, Chembio Diagnostics, Inc., EKF Diagnostics Holdings plc., Trinity Biotech, Fluxergy, Thermo Fisher Scientific, Quest Diagnostics Incorporated, DiaSys Diagnostics India Pvt Ltd., Cipla, Sysmex Europe SE, Lumos Diagnostics™, Trivitron Healthcare, Getein Biotech, Inc., ACON Laboratories, Inc., and others
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Which MedTech key players in the Point of Care Diagnostics market are set to emerge as the trendsetter explore @ Point of Care Diagnostics Manufacturer
https://www.delveinsight.com/sample-request/point-of-care-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Point of Care Diagnostics Market Report Introduction
2 Point of Care Diagnostics Market Executive summary
3 Regulatory and Patent Analysis
4 Point of Care Diagnostics Market Key Factors Analysis
5 Porter's Five Forces Analysis
6 COVID-19 Impact Analysis on Point of Care Diagnostics Market
7 Point of Care Diagnostics Market Layout
8 Global Company Share Analysis - Key 3-5 Companies
9 Company and Product Profiles
10 Point of Care Diagnostics Market Drivers
11. Point of Care Diagnostics Market Barriers
12. Project Approach
13. About DelveInsight

Interested in knowing how the Point of Care Diagnostics market will grow by 2028? Click to get a snapshot of the Point of Care Diagnostics Market Analysis
https://www.delveinsight.com/sample-request/cancer-immunotherapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Latest Reports Offered By DelveInsight:

Oncology Drugs Market
https://www.delveinsight.com/report-store/oncology-drugs-market
Oncology Drugs Market By Therapy Type (Chemotherapy, Hormonal Therapy, Targeted Therapy [Gene Therapy And Immunotherapy], And Others), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancers, And Others), By End User (Hospitals, Specialty Clinics, And Others), and by geography is estimated to grow at a healthy CAGR forecast till 2028 due to rising prevalence of various cancers such as lung and breast cancers and growing demand for targeted therapies for cancer treatment.

Biologics Market
https://www.delveinsight.com/report-store/biologics-market
Biologics Market By Product Type (Cell-Based Biologics, Gene-Based Biologics, Monoclonal Antibodies, Vaccines, Recombinant Protiens, And Others), By Application (Oncology, Immunology, Infectious Diseases, Neurological Diseases, And Others), By Manufacturing Type (In-House And Outsourced), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to rising prevalence of autoimmune disorders such as rheumatoid arthiritis and genetic disorders.

Biosimilar Market
https://www.delveinsight.com/report-store/biosimilars-market
Biosimilars Market By Product Class (Monoclonal Antibodies, Recombinant Hormone/Proteins, Anti-Inflammatory Agents, Immunomodulators, And Others), By Manufacturing Type (In-House And Outsourced/Contract), By Application (Autoimmune Diseases, Blood Disorders, Oncology, Infectious Diseases, And Others), by geography, is projected to expand at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders such as autoimmune disorders, cancers, among others and increasing demand for biosimilar drugs owing to their cost-effectiveness.

Cancer Immunotherapy Market
https://www.delveinsight.com/report-store/cancer-immunotherapy-market
Cancer Immunotherapy Market By Type (Monoclonal Antibodies, Immunomodulators, Cancer Vaccines, Checkpoint Inhibitors, And Others), By Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, And Others), By End-User (Hospitals And Clinics, Specialty Centers, And Others), and by geography is expected to rise at a significant CAGR forecast till 2027 owing to the accelerating prevalence of cancers and surging healthcare expenditure across the globe

Companion Diagnostics Market
https://www.delveinsight.com/report-store/companion-diagnostics-market
Companion Diagnostics Market By Type (Product [Assays, Kits & Reagents And Instruments], and Services), Technology (Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Others), Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, and Others), End-User (Hospitals, Diagnostic Labs, and Others), and Geography is expected to grow at a noteworthy CAGR till 2028 owing to the increase in the cancer burden across the globe and the growing focus on personalized medicines.

Contact Us
Gaurav Bora
info@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/medical-devices

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.